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Influence of Gender in MUSTT. Introduction: Previous studies have demonstrated gender differences
in risk of sudden death in patients with ischemic heart disease. The Multicenter UnSustained Tachycardia
Trial (MUSTT) evaluated the ability of therapy guided by electrophysiologic (EP) testing to reduce mortal-
ity in patients with coronary disease, ejection fraction ≤40%, and spontaneous nonsustained ventricular
tachycardia.
Methods and Results: We analyzed the influence of gender on results of EP testing and outcome of patients
enrolled in MUSTT. Women made up 14% of the overall MUSTT population and were less likely than men
to have inducible sustained randomizable ventricular arrhythmias (24% vs 36%, P < 0.001). Baseline
characteristics differed between men and women. In randomized patients, women were older, more likely
to have had an infarction within 6 months, more likely to have a history of heart failure, and more likely
to have recent angina prior to enrollment than men (P < 0.05). In the EP-guided therapy group, there was
no difference in implantable cardioverter defibrillator implantation rate in men and women (45% vs 53%,
P = 0.38). There also were no significant gender influences on risk of arrhythmic death or cardiac arrest
(2-year event rate 9% in women and 12% in men, adjusted hazard ratio 0.88) or overall mortality (2-year
event rate 32% in women vs 21% in men, adjusted hazard ratio 1.51).
Conclusion: The outcome and benefit of EP-guided therapy in this trial did not appear to be influenced
by gender. However, due to the small numbers of women in the trial, small differences in outcome may not
be apparent. Plans for future primary prevention trials should include careful risk stratification of women
who less often have inducible sustained ventricular arrhythmias and better left ventricular function despite
more frequent heart failure. (J Cardiovasc Electrophysiol, Vol. 15, pp. 993-998, September 2004)
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Introduction
Previous studies have raised concern regarding possible
gender bias with respect to evaluation and treatment of car-
diovascular disease, including referral for diagnostic cardiac
catheterization, thrombolytic therapy for acute myocardial
infarction (MI), and revascularization procedures for coro-
nary artery disease.1-6 Women have greater morbidity and
mortality associated with MI.7 It has been suggested that
there is gender bias in referral for invasive treatment, and this
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may have an impact on outcome. However, these gender dif-
ferences in referral for invasive procedures or differences in
outcome are explained, at least in part, on the basis of age,
severity of coronary disease, or presence of other concomitant
risk factors.7-10
Gender differences in the incidence of sudden death and
risk factors for development of sustained ventricular arrhyth-
mias have been previously described.11,12 The incidence of
sudden cardiac death is lower in women than in men, compris-
ing one third of all coronary heart disease deaths in women
compared to one half in men.11 There appears to be a 20-year
lag in the incidence of sudden cardiac death in women in com-
parison to men.12 This may be due to the protective effects
of sex steroids on development of coronary artery disease.
The Multicenter UnSustained Tachycardia Trial
(MUSTT) was a primary prevention trial that demon-
strated the benefit of electrophysiologically (EP)-guided
therapy for patients with coronary artery disease, reduced
left ventricular function, and asymptomatic nonsustained
ventricular tachycardia (NSVT).13 Patients with inducible
sustained ventricular tachycardia (VT) had a high mortality
rate, which was lowered by treatment with implantable
cardioverter defibrillators (ICDs) but not by antiarrhythmic
drug therapy. The purpose of the current analysis was to
determine the influence of gender on patient characteristics,
treatment, and outcome of patients enrolled into this trial.
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Methods
The MUSTT protocol has been described previously.13,14
This was a National Institutes of Health-sponsored, multi-
center, randomized trial that evaluated the role of EP-guided
antiarrhythmic therapy in patients with inducible sustained
ventricular arrhythmias. Patients were eligible for enrollment
if they had coronary artery disease, left ventricular ejection
fraction (LVEF) ≤40%, asymptomatic NSVT, and no his-
tory of spontaneous sustained VT, syncope, or cardiac arrest,
except in the setting of an acute MI. Patients who had in-
ducible sustained VT were randomized to a standard medical
regimen, which included treatment with beta-blockers and
angiotensin-converting enzyme inhibitors, versus the same
regimen with the addition of EP-guided therapy. EP-guided
therapy included antiarrhythmic drug treatment or ICD ther-
apy for patients who did not respond to antiarrhythmic drugs
at the time of EP testing.
Patients were eligible for randomization if they had sus-
tained monomorphic VT that was reproducibly inducible
with single, double, or triple extrastimuli, or with burst pac-
ing. If sustained polymorphic VT was reproducibly inducible
with single or double extrastimuli, patients were eligible for
randomization. Patients who refused randomization after in-
duction of sustained VT were followed in a registry. Patients
without any inducible sustained ventricular arrhythmias also
were followed in the registry. In addition, patients with sus-
tained polymorphic VT inducible with triple extrastimuli
were not eligible for randomization and were followed in
a registry.
Patients
A total of 2,202 patients were enrolled in the trial at 85
sites, including 704 patients with inducible sustained VT who
were randomized as described earlier. The remaining 1,498
patients were followed in a registry without antiarrhythmic
therapy.13
Statistical Analysis
Values for continuous variables are presented as medi-
ans with 25th and 75th percentiles. Values for categorical
variables are presented as percentages. Differences in clini-
cal characteristics and discharge medications between gen-
der groups were assessed using the Wilcoxon rank sum test
(for continuous variables) and the Chi-square test (for cate-
gorical variables). All tests of significance were two tailed.
Cumulative event rates and survival curves were calculated
by the Kaplan-Meier method, and outcome differences were
assessed with the log rank test. In addition, covariate-adjusted
analyses of outcomes were performed with the Cox pro-
portional hazards model. Covariates included in these anal-
yses were the induction of randomizable VT, age, ejec-
tion fraction, race, prior bypass surgery, prior angioplasty,
prior MI, number of vessels with >75% stenosis, duration
(in beats) of the longest episode of NSVT, symptoms of
angina within 6 weeks of enrollment, left bundle branch
block, intraventricular conduction delays, and use of digi-
talis at baseline. Hazard ratios and 95% confidence inter-
vals also were calculated using the Cox proportional hazards
model.
TABLE 1
Gender Differences in Enrollment: Randomized and Registry Patients
Men Women
Entire study (N = 2,202) 1,901 (86%) 301 (14%)
Randomized (N = 704) 636 (90%) 68 (10%)
Registry (N = 1,498) 1,265 (84%) 233 (16%)
Inducible (N = 101) 91 10
Noninducible (N = 1,397) 1,174 223
Results
Overall Population: Randomized Versus Registry
A total of 301 women were enrolled in the trial, repre-
senting 14% of the total study population (Table 1). Ten
percent of patients enrolled in the randomized group were
women, whereas 16% of those in the registry were women
(P = 0.001). Enrollment refusal forms were received from
856 patients (660 men and 160 women). Of the patients who
refused enrollment, 10% of women and 15% of men under-
went a baseline EP study (P = 0.083). For patients who un-
derwent baseline EP testing in the enrollment refusal group,
86% of women and 65% of men had inducible sustained
VT (P = 0.098). For those who refused enrollment, 19%
of women compared to 10% of men were non-Caucasian
(P = 0.002). Sufficient information regarding specific rea-
sons for enrollment refusal is not available to allow adequate
comparisons between men and women.
Baseline Characteristics
Within the randomized group, there were no significant
differences in LVEF, race, presence of three-vessel coronary
artery disease, prior coronary artery bypass graft or other
revascularization, ECG conduction delays, or left ventricu-
lar hypertrophy between men and women (Table 2). Women
were older, more likely to have had an MI within 6 months
of enrollment, more likely to have experienced angina within
6 weeks prior to enrollment, and less likely to have atrial
fibrillation than men.
Within the registry, there were no significant differences
with regard to age, presence of three-vessel coronary artery
disease, or percentage of patients who experienced angina
within 6 weeks prior to enrollment in men and women. How-
ever, women had a higher LVEF and were more often non-
Caucasian, less likely to have undergone prior coronary artery
bypass graft or other revascularization, more likely to have
suffered an MI within 6 months of enrollment, and more
likely to have a left bundle branch block than men (Table 2).
Although data regarding the clinical history of congestive
heart failure (CHF) were not collected on all patients, for
patients in whom data were available, there was a significant
difference in the prevalence of CHF between men and women
in the randomized group. In the randomized patients, 88% of
females and 69% of males had a history of CHF (P = 0.008).
In registry patients, 75% of females and 67% of males had a
history of CHF (P = 0.111).
EP Testing
Men were more likely to have inducible sustained VT than
women. Thirty-six percent of men versus 24% of women had
inducible randomizable VT (P = 0.001). It should be noted
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TABLE 2
Clinical Characteristics of the Patients at Baseline
Randomized Registry
Men (n = 636) Women (n = 68) P Value Men (n = 1,265) Women (n = 233) P Value
Age <70 years 67% 53% 0.022 66% 67% 0.77
Left ventricular ejection fraction <30% 51% 44% 0.30 51% 44% 0.046
Caucasian 89% 82% 0.14 86% 76% 0.001
Three-vessel coronary artery disease 43% 39% 0.58 39% 34% 0.14
Prior coronary artery bypass graft 55% 59% 0.58 64% 52% 0.001
Prior revascularization∗ 66% 65% 0.79 75% 64% 0.001
Myocardial infarction to enrollment ≤6 months 30% 47% 0.010 31% 40% 0.021
Angina last 6 weeks 38% 51% 0.026 35% 33% 0.56
History of congestive heart failure 69% (n = 372) 88% (n = 43) 0.008 67% (n = 670) 75% (n = 115) 0.111
ECG characteristics
Left bundle branch block 6% 5% 0.76 5% 11% 0.001
Intraventricular conduction delay 21% 15% 0.32 18% 13% 0.10
Atrial fibrillation 6% 0 0.044 9% 8% 0.70
Left ventricular hypertrophy 37% 34% 0.61 46% 46% 0.94
∗Includes coronary artery bypass graft and percutaneous revascularization.
that the higher percentage of women in the registry is due
at least in part to this higher noninducibility rate in women.
There was no difference in the type of VT induced in the ran-
domized group. Ninety percent of men and 91% of women
had sustained monomorphic VT induced; the remainder had
sustained polymorphic VT induced (P = NS). Similarly, in
registry patients, there was no difference in the percentage
of men or women who had inducible sustained monomor-
phic VT.
Nonantiarrhythmic Medical Therapy
In the EP-guided therapy group, women were more
likely to be discharged on diuretic therapy than men
(Table 3). Except for diuretic therapy, there were no other
differences between men and women with respect to dis-
charge nonantiarrhythmic medical therapy in the EP-guided
therapy versus no EP-guided therapy group. In the reg-
istry, women were more likely to be discharged on calcium
channel blockers, digoxin, diuretics, and nitrates than men
(P < 0.05; Table 3).
Antiarrhythmic Drug Therapy
Among patients randomized to EP-guided therapy, 32% of
women were discharged with pharmacologic antiarrhythmic
therapy versus 46% of men (P = 0.12). There were no signifi-
cant differences between men and women with respect to the
number of antiarrhythmic drug trials or percentage of men




Guided Therapy Guided Therapy Registry
Men Women P Men Women P Men Women P
(n = 319) (n = 34) Value (n = 317) (n = 34) Value (n = 1,265) (n = 233) Value
Beta-blockers 51% 50% 0.88 30% 18% 0.13 36% 30% 0.13
Angiotensin-converting enzyme inhibitors 76% 85% 0.22 72% 71% 0.84 72% 76% 0.16
Aspirin 62% 71% 0.35 63% 71% 0.37 62% 56% 0.10
Calcium channel blockers 25% 24% 0.89 21% 29% 0.25 18% 26% 0.004
Digitalis 53% 59% 0.50 50% 65% 0.11 55% 63% 0.030
Diuretics 56% 74% 0.055 56% 76% 0.025 57% 66% 0.017
Nitrates 43% 53% 0.26 38% 50% 0.18 40% 49% 0.020
arrhythmias after the first and last antiarrhythmic drug tri-
als in the EP-guided therapy group. There was no difference
between men and women with regard to the type of antiar-
rhythmic agents utilized.
Outcome: Arrhythmic Death or Cardiac Arrest
There were no gender differences in event-free survival
from arrhythmic death or cardiac arrest in either the random-
ized or the registry patients (Fig. 1, Table 4). Within the ran-
domized group, there were no differences in survival free of
arrhythmic death or cardiac arrest between men and women
who received EP-guided therapy or in those who received no
EP-guided therapy (Table 4).
Outcome: Total Mortality
There were no significant gender differences in all-cause
mortality in either the randomized or the registry patients
(Table 4, Fig. 2). There was a trend toward a slightly higher
overall mortality in women compared to men in the reg-
istry (27% vs 20%) and those who received EP-guided
therapy (32% vs 21%), although this was not significant
(adjusted P = 0.13 and 0.15, respectively). Within the ran-
domized group, there were no differences in mortality be-
tween men and women who received EP-guided therapy and
between men and women who received no EP-guided ther-
apy. The interaction of treatment and gender was not signifi-
cant (P = 0.12).
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Figure 1. Survival free from arrhythmic death or cardiac arrest in all pa-
tients. There was no difference in 5-year survival free of arrhythmic death
or cardiac arrest in men compared to women in the electrophysiologically
guided therapy group (P = 0.35).
Treatment: Type of EP-Guided Therapy and ICD
Implantation
The type of therapy prescribed to men and women
in the EP-guided therapy group was examined. At the
time of hospital discharge, there was no significant dif-
ference between women and men with respect to the per-
centage of patients for whom ICDs were recommended
in the EP-guided therapy group (21/34 [62%] patients vs
163/317 [51%] patients, P = 0.25). There was no differ-
ence in the patient refusal rate for ICD implantation in
women versus men (3/34 [9%] women vs 20/317 [6%] men,
P = 0.79).
At the time of hospital discharge, 45% of men and 53%
of women had received ICDs in the EP-guided therapy group
(P = 0.38). An additional 41 men (13%) received ICDs after
hospital discharge; 23 were implanted after an event (cardiac
arrest, sustained VT, or syncope), and the remaining 18 were
implanted for unknown reasons. No women received ICDs
after hospital discharge. Thus, a total of 58% of men and 53%
TABLE 4
Two-Year and Five-Year Event Rates by Gender
Men Women
2-Year/5-Year 2-Year/5-Year Adjusted∗ Adjusted∗
N Event Rate N Event Rate Hazard Ratio (95% CI) P Value
Arrhythmic Death or Cardiac Arrest
Registry patients† 1,174 0.12/0.25 223 0.13/0.23 1.03 (0.73, 1.45) 0.87
No electrophysiologically guided therapy 319 0.18/0.34 34 0.13/0.21 0.69 (0.29, 1.61) 0.39
Electrophysiologically guided therapy 317 0.12/0.25 34 0.09/0.26 0.88 (0.35, 2.23) 0.78
Total Mortality
Registry patients† 1,174 0.20/0.44 223 0.27/0.47 1.19 (0.95, 1.49) 0.13
No electrophysiologically guided therapy 319 0.29/0.50 34 0.24/0.34 0.71 (0.39, 1.30) 0.27
Electrophysiologically guided therapy 317 0.21/0.41 34 0.32/0.53 1.51 (0.86, 2.64) 0.15
∗Adjusted for induction of randomizable ventricular tachycardia, age, ejection fraction, race, prior myocardial infarction, prior coronary artery bypass graft
surgery, prior percutaneous intervention (PCI) , number of diseased vessels (>75% stenosed), digitalis at baseline, intraventricular conduction delay, left
bundle branch block, angina within 6 weeks of enrollment, longest episode of nonsustained ventricular tachycardia.
†Noninducible registry patients.
of women had ICDs implanted at some point during the study
(P = 0.57).
Discussion
We have demonstrated that gender influences many impor-
tant characteristics of patients enrolled in MUSTT. In spite of
these differences, the risk of mortality and arrhythmic events
in the trial appears to be similar for men and women. How-
ever, it should be recognized that a lack of power, particu-
larly regarding arrhythmic events and mortality, could prevent
identification of a significant difference in outcome, due to
the small number of women enrolled.
The reason why a relatively small percentage of women
was enrolled in this trial likely is related to the higher preva-
lence of coronary artery disease in men. A significantly higher
percentage of women was enrolled in the registry compared
to the randomized group, reflecting the lower rate of inducing
randomizable VT in women. However, the contribution of a
higher refusal rate of women for enrollment in the random-
ized group or physician bias cannot be excluded, because
complete refusal data are not available. Enrollment refusal
also may be confounded by racial differences, as a higher
percentage of non-Caucasian women compared to men re-
fused enrollment.
Gender differences in baseline characteristics have been
identified previously in cardiac arrest survivors.15-18 Studies
have shown that women cardiac arrest survivors have a lower
prevalence of coronary disease and may have a higher LVEF
than men.15-17 In the Antiarrhythmics Versus Implantable De-
fibrillator (AVID) trial, women were younger, more likely to
have a nonischemic dilated cardiomyopathy, and more likely
had ventricular fibrillation rather than VT as the index ar-
rhythmia.15
In the current study, women in the randomized group were
older and more likely to have experienced a recent MI or
recent angina than men. The use of nonantiarrhythmic drugs,
such as digitalis and diuretics, was higher in women. There
was a significantly higher prevalence of a history of CHF
in women compared to men in the randomized group. We
also found that women were less likely to have inducible
sustained ventricular tachyarrhythmias, which is similar to
results of previous retrospective studies.16,17,19,20
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Figure 2. Overall survival in all patients. There was no significant difference
in 5-year overall survival for women compared to men in the randomized
and registry groups examined together (P = 0.37).
With respect to the type of EP-guided therapy, we did not
observe gender bias related to ICD implantation rates in the
current primary prevention trial. This is similar to previous
secondary prevention trials, which demonstrated no signifi-
cant gender differences in ICD implantation rates.15,16 In the
present study, there were no differences with respect to ICD
recommendations or refusal in women compared to men. In
contrast, women refused ICD implantation more often than
men (19% vs 2%, P = 0.01) in one previous study.21
In the current study, there appeared to be no gender dif-
ferences with regard to overall mortality or occurrence of ar-
rhythmic death or cardiac arrest, despite gender differences in
baseline characteristics and inducibility. Similar to the current
analysis, mortality was similar in women (14.4%) and men
(15.5%) in AVID, a secondary prevention trial, despite gender
differences in baseline characteristics and clinical arrhythmia
at the time of presentation.15 In a retrospective review of pa-
tients enrolled in clinical studies designed to evaluate new
ICDs or defibrillation leads, Pires et al.22 demonstrated that
men and women with a variety of clinical presentations and
types of heart disease had similar sudden and cardiac death-
free survival rates during a mean follow-up period of <1 year.
Consistent with the current study, MADIT II demonstrated
that the benefit of defibrillator therapy on survival was simi-
lar in men and women with coronary disease who underwent
device implantation for primary prevention.23
Study Limitations
This is a post hoc analysis of patients enrolled in MUSTT.
The greatest limitation of this analysis is the small number
of women enrolled in the trial, particularly the small number
of women who received ICDs. Therefore, small differences
in outcome may not be apparent.
Conclusion
Marked differences in inducibility of sustained VT, as
well as other differences in characteristics between men and
women, were observed in this trial. Despite these gender
differences, EP-guided therapy, which includes a relatively
“nonspecific” treatment with ICD implantation, appears to
offer equal protection against arrhythmic death in men and
women. Although the small number of women in this trial
makes it difficult to draw any firm conclusions regarding gen-
der differences in outcome, these results should be viewed as
interesting preliminary data that are hypothesis-generating
for examination in future trials. Risk stratification in women
may need to be reconsidered to reflect that fact that women
less often have inducible VT and often have a higher ejec-
tion fraction despite a more frequent history of heart failure.
Further investigation also is warranted to determine whether
gender differences in outcome might be apparent with dif-
ferent arrhythmia substrates or other types of heart disease,
including patients with nonischemic dilated cardiomyopathy.
Other multicenter primary prevention trials, such as the Sud-
den Cardiac Death in Heart Failure Trial (SCD-HeFT), may
help answer these questions.
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